Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

5 results
Display

Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer

Lee JH, Oh YM, Lee SD, Lee JS

BACKGROUND: Low-molecular-weight heparin (LMWH) is the standard treatment for venous thromboembolism (VTE) in patients with active cancer. However, use of factor Xa inhibitors, such as rivaroxaban, is increasing on the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients

Joung B

Regulatory approvals of non-vitamin K antagonist oral anticoagulants (NOACs) have been based on large randomized phase III trials evaluating dabigatran, rivaroxaban, apixaban, or edoxaban relative to warfarin for atrial fibrillation...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Series with complete resolution of left atrial appendage thrombi with apixaban in elderly patients

Lee SH, Han S

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Guidance for Endoscopic Procedures in Patients Taking Novel Oral Anticoagulants

Kim KO

Anticoagulant agents are used to reduce the risk of thromboembolic complications in patients with atrial fibrillation or deep vein thrombosis. Several new generation of oral anticoagulants have been approved. These...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban

Yang H, Kim SR, Song MJ

Cirrhosis can occur with the development of portal vein thrombosis (PVT). PVT may aggravate portal hypertension, and it can lead to hepatic decompensation. The international guideline recommends for anticoagulation treatment...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr